



The Specialist  
in Cancer Care

March 29, 2017

To  
**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051,  
Maharashtra, India

To  
**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001,  
Maharashtra, India

Dear Sir/Madam,

**Sub :** Press Release.

**Ref :** HealthCare Global Enterprises Limited (“the Company”)

**Scrip Code :** NSE Scrip Code: HCG; BSE Scrip Code: 539787

Further to the intimation made by the Company on the execution of Share Purchase Agreement (“SPA”) and Shareholders’ and Subscription Agreement (“SSA”) by HealthCare Global (Kenya) Private Limited (“HCG Kenya”), step down subsidiary of the Company, with Cancer Care Kenya Limited (“CCK”) and its existing shareholders, relating to the investment in the share capital of CCK, please find enclosed herewith the release to the press being made, in this regard.

Request you to take this on record.

Thanking You,

For HealthCare Global Enterprises Limited

**Sunu Manuel**  
Company Secretary & Compliance Officer



Encl: as above

**HealthCare Global Enterprises Ltd.**

HCG Tower, No. 8, P. Kallinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027 | PAN No AAACC8412H  
91 80 3366 9999 | Info@hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bangalore | Bhavnagar | Chennai | Cuttack | Delhi | Hubli | Kanpur | Kenya | Kolkata | Mangalore | Mumbai | Mysore | Nasik | Ongole | Ranchi | Shimoga | Tanzania | Trichy | Uganda | Vijayawada | Vizag



## Press Release

### **HCG plans to acquire a majority stake in Cancer Care Kenya**

**Bengaluru, March 29<sup>th</sup>, 2017 – HealthCare Global Enterprises Ltd (HCG)** today announced that it has entered into definitive agreements to acquire a majority stake in Cancer Care Kenya Limited (CCK) a leading cancer centre in Nairobi, Kenya, subject to review and approval by the Competition Authority of Kenya and other requisite approvals.

CDC, the development finance institution of the UK Government, which has partnered with HCG for Africa investments, through an investment in a HCG off-shore subsidiary that will make the acquisition, and MP Shah Hospital, a leading tertiary care hospital in Kenya, will also participate in the transaction. Dr. N. Adamali, the founder of CCK, will retain his shareholding in the company post acquisition and will continue his association.

CCK, which started operation in 2010 is the first private comprehensive cancer centre in the country. CCK treats over a thousand patients annually including over two hundred patients from other African nations. CCK's team includes internationally trained radiation, medical and surgical oncologists, physicists, radiation technicians and oncology nurses.

Commenting on the development, **Dr. B.S. Ajaikumar, Chairman of HCG** said, "There are over 250,000 new cancer incidences each year in Eastern Africa – resulting in a huge and growing unmet need for advanced cancer care. Thousands of patients travel overseas for treatment, due to the lack of access to advanced cancer care. HCG has been treating patients from Africa in India for several years now, and have been enthused by the positive results and the strong response from the medical community in these countries. To ensure the best clinical outcomes, we have been seeking to find the right opportunities to establish advanced treatment options in the region. We are thus excited by the opportunity to partner with a highly regarded group like CCK and look forward to working closely with our partners, Dr. Adamali, CDC and MP Shah Hospital to bring in the highest standards of excellence in cancer care in Africa and further out mission to make high quality cancer care accessible to all."

#### **About HCG Enterprises Ltd:**

Healthcare Global Enterprises Ltd. (HCG), headquartered in Bangalore, is the largest provider of cancer care in India. Through its network of 17 comprehensive cancer centres spread across India, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centres provide expertise and the latest technologies in diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer.

#### **For further information, please contact:**

Nilofer Mendonca | [nilofer.m@hcgoncology.com](mailto:nilofer.m@hcgoncology.com) | +91-9620899970  
Souvik Chakraborty | [souvik.c@hcgoncology.com](mailto:souvik.c@hcgoncology.com) | +91-9886312419